X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14168) 14168
Magazine Article (127) 127
Newsletter (89) 89
Newspaper Article (42) 42
Transcript (30) 30
Book Chapter (12) 12
Publication (2) 2
Book / eBook (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12955) 12955
male (8651) 8651
female (7898) 7898
middle aged (6086) 6086
adult (5602) 5602
prednisone - therapeutic use (5353) 5353
prednisone - adverse effects (4610) 4610
aged (4343) 4343
prednisone - administration & dosage (4125) 4125
prednisone (4119) 4119
treatment outcome (2751) 2751
antineoplastic combined chemotherapy protocols - therapeutic use (2638) 2638
oncology (2534) 2534
adolescent (2497) 2497
antineoplastic combined chemotherapy protocols - adverse effects (2121) 2121
chemotherapy (1877) 1877
child (1865) 1865
vincristine - administration & dosage (1768) 1768
corticosteroids (1738) 1738
therapy (1734) 1734
hematology (1677) 1677
cyclophosphamide - administration & dosage (1668) 1668
drug therapy, combination (1659) 1659
aged, 80 and over (1379) 1379
doxorubicin - administration & dosage (1338) 1338
retrospective studies (1338) 1338
cyclophosphamide - adverse effects (1337) 1337
vincristine - adverse effects (1318) 1318
follow-up studies (1309) 1309
cancer (1271) 1271
immunosuppressive agents - therapeutic use (1241) 1241
care and treatment (1222) 1222
time factors (1163) 1163
child, preschool (1131) 1131
prognosis (1114) 1114
transplantation (1058) 1058
antineoplastic combined chemotherapy protocols - administration & dosage (1031) 1031
cyclophosphamide - therapeutic use (1030) 1030
drug administration schedule (1005) 1005
medicine, general & internal (984) 984
glucocorticoids - therapeutic use (960) 960
doxorubicin - adverse effects (956) 956
risk factors (951) 951
immunosuppressive agents - adverse effects (950) 950
prostate cancer (926) 926
drug therapy (902) 902
prospective studies (891) 891
survival (855) 855
vincristine - therapeutic use (854) 854
cyclophosphamide (845) 845
rituximab (836) 836
glucocorticoids - adverse effects (781) 781
anti-inflammatory agents - therapeutic use (750) 750
immunology (743) 743
disease-free survival (739) 739
dose-response relationship, drug (736) 736
medicine & public health (733) 733
remission induction (733) 733
urology & nephrology (727) 727
recurrence (721) 721
patients (715) 715
azathioprine - therapeutic use (704) 704
combined modality therapy (694) 694
rheumatology (694) 694
survival analysis (692) 692
kidney transplantation (689) 689
disease (686) 686
pediatrics (685) 685
docetaxel (679) 679
research (663) 663
antineoplastic agents - therapeutic use (653) 653
surgery (644) 644
children (633) 633
trial (633) 633
young adult (631) 631
survival rate (628) 628
administration, oral (617) 617
infant (616) 616
animals (614) 614
analysis (602) 602
steroids (599) 599
clinical trials (596) 596
health aspects (596) 596
lymphoma, non-hodgkin - drug therapy (591) 591
antineoplastic agents - adverse effects (589) 589
doxorubicin - therapeutic use (585) 585
double-blind (578) 578
hodgkin disease - drug therapy (578) 578
glucocorticoids - administration & dosage (569) 569
lymphomas (561) 561
neoplasm staging (551) 551
methotrexate - administration & dosage (539) 539
lymphoma, large b-cell, diffuse - drug therapy (535) 535
pharmacology & pharmacy (527) 527
biopsy (526) 526
multiple myeloma - drug therapy (517) 517
clinical trials as topic (516) 516
prostatic neoplasms - drug therapy (512) 512
mitoxantrone (492) 492
abridged index medicus (491) 491
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13074) 13074
German (380) 380
French (349) 349
Spanish (199) 199
Polish (112) 112
Chinese (85) 85
Japanese (78) 78
Italian (75) 75
Russian (35) 35
Dutch (32) 32
Czech (26) 26
Portuguese (24) 24
Danish (21) 21
Norwegian (16) 16
Hebrew (10) 10
Hungarian (8) 8
Romanian (8) 8
Slovak (6) 6
Serbian (4) 4
Croatian (3) 3
Swedish (3) 3
Korean (2) 2
Bulgarian (1) 1
Finnish (1) 1
Thai (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 5, pp. 592 - 598
Purpose To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive... 
2ND CANCER-RISK | RANDOMIZED-TRIALS | ONCOLOGY | DNA TOPOISOMERASE-II | ALKYLATING-AGENTS | COMBINED-MODALITY TREATMENT | DISEASE | MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROMES | CHEMOTHERAPY | ACUTE PROMYELOCYTIC LEUKEMIA | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Leukemia, Myeloid, Acute - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Mechlorethamine - adverse effects | Male | Risk | Leukemia, Myeloid, Acute - etiology | Incidence | Hodgkin Disease - radiotherapy | Melphalan - adverse effects | Chemotherapy, Adjuvant - adverse effects | Radiotherapy, Adjuvant - adverse effects | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Retrospective Studies | Databases, Factual | Radiotherapy Dosage | Prednisone - adverse effects | Drug Administration Schedule | California - epidemiology | Clinical Trials as Topic | Bleomycin - adverse effects | Academic Medical Centers | Myelodysplastic Syndromes - epidemiology | Myelodysplastic Syndromes - etiology | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Methotrexate - adverse effects | Procarbazine - adverse effects | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Hema14 | Hema13 | Hema12 | ORIGINAL REPORTS
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 3, pp. 203 - 212
.... BEACOPP therapy was associated with higher initial rates of complete response and freedom from relapse but also with more short-term and long-term toxic effects... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 11, p. CD008727
Background Glucocorticoids play a major role in the treatment of acute lymphoblastic leukaemia (ALL). However, supraphysiological doses can suppress the... 
Antineoplastic Agents, Hormonal | Dexamethasone | Fluconazole | Glucocorticoids | Childhood cancers | Pituitary‐Adrenal System | Supportive care: therapy‐related side effects during treatment | Prednisone | Randomized Controlled Trials as Topic | Supportive care: side effects of cancer treatment | Adrenal Insufficiency | Blood disorders | Precursor Cell Lymphoblastic Leukemia‐Lymphoma | Hypothalamo‐Hypophyseal System | Child health | Observational Studies as Topic | Supportive care | Acute lymphoblastic leukaemia | Medicine General & Introductory Medical Sciences | Haematological malignancies | Late effects: therapy‐related side effects after treatment | Prednisolone | Cohort Studies | Cancer | GLUCAGON STIMULATION TEST | 250 MU-G | Humans | 1ST REMISSION | Antineoplastic Agents | INSUFFICIENCY | DEATH | Glucocorticoids [administration & dosage; adverse effects] | CHILDREN | MEDICINE, GENERAL & INTERNAL | Prednisolone [administration & dosage; adverse effects] | GROWTH-HORMONE | INDUCTION THERAPY | Hypothalamo-Hypophyseal System [drug effects] | ADRENOCORTICAL RECOVERY | Precursor Cell Lymphoblastic Leukemia-Lymphoma [drug therapy] | Hormonal [administration & dosage; adverse effects] | Pituitary-Adrenal System [drug effects] | Dexamethasone [administration & dosage; adverse effects] | Child | Adrenal Insufficiency [chemically induced] | CORTISOL | Hypothalamo-Hypophyseal System - drug effects | Prednisolone - adverse effects | Glucocorticoids - administration & dosage | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisolone - administration & dosage | Prednisone - adverse effects | Pituitary-Adrenal System - drug effects | Antineoplastic Agents, Hormonal - administration & dosage | Fluconazole - administration & dosage | Dexamethasone - adverse effects | Fluconazole - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Adrenal Insufficiency - chemically induced | Glucocorticoids - adverse effects
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2013, Volume 24, Issue 9, pp. 2421 - 2425
.... Inhibitors of mTOR have immunosuppressive and anti-cancer effects, but their effects on the progression of kidney disease are not fully understood... 
Acute tubular necrosis | Acute renal failure | MTOR | MORTALITY | ACUTE KIDNEY INJURY | RECOVERY | acute renal failure | EVEROLIMUS | ONCOLOGY | mTOR | acute tubular necrosis | DEATH | Doxorubicin - therapeutic use | Lung Neoplasms - drug therapy | Glutamates - adverse effects | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Cyclophosphamide - adverse effects | Sunitinib | Nephrectomy | Diphosphonates - therapeutic use | Pyrroles - adverse effects | Imidazoles - therapeutic use | Kidney Tubules - pathology | Guanine - therapeutic use | Prednisone - adverse effects | Bone Density Conservation Agents - adverse effects | Kidney Tubules - drug effects | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Zoledronic Acid | Adenocarcinoma - drug therapy | Pemetrexed | Indoles - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Indoles - therapeutic use | Prednisone - therapeutic use | Glutamates - therapeutic use | Adenocarcinoma of Lung | Guanine - analogs & derivatives | Interferons - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - surgery | Cyclophosphamide - therapeutic use | Necrosis | TOR Serine-Threonine Kinases - antagonists & inhibitors | Mediastinal Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Female | Acute Kidney Injury - chemically induced | Guanine - adverse effects | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Diphosphonates - adverse effects | Lymphoma, B-Cell - drug therapy | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Doxorubicin - adverse effects
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 32, pp. 3651 - 3658
Purpose The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy response in... 
TRIAL | MORTALITY | ABVD | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | INVOLVED-FIELD RADIATION | PEDIATRIC-PATIENTS | DISEASE | FOLLOW-UP | CHILDHOOD-CANCER SURVIVOR | NO RADIOTHERAPY | Cyclophosphamide - administration & dosage | Hodgkin Disease - pathology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Hodgkin Disease - radiotherapy | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Female | Child | Infant, Newborn | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Cisplatin - adverse effects | Vincristine - adverse effects | Doxorubicin - adverse effects | Pedi9 | ORIGINAL REPORTS | Hema14
Journal Article
Mayo Clinic proceedings, ISSN 0025-6196, 2006, Volume 81, Issue 10, pp. 1361 - 1367
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 2, pp. 231 - 239
Purpose To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy... 
INHIBIN-B | PRESERVATION | OUTCOME MEASURE | OVARIAN RESERVE | ONCOLOGY | TERM FOLLOW-UP | DISEASE | FEMALE CANCER SURVIVORS | ANTI-MULLERIAN HORMONE | CHEMOTHERAPY | SERUM MARKER | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Gonadotropin-Releasing Hormone - analogs & derivatives | Fertility - physiology | Fertility Preservation | Young Adult | Vinblastine - adverse effects | Follicle Stimulating Hormone - blood | Hodgkin Disease - drug therapy | Oligospermia - epidemiology | Vincristine - administration & dosage | Adult | Female | Gonadotropin-Releasing Hormone - therapeutic use | Hodgkin Disease - physiopathology | Inhibins - blood | Menstrual Cycle - drug effects | Testosterone - blood | Menstrual Cycle - physiology | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Survivors | Etoposide - administration & dosage | Ovary - physiology | Hodgkin Disease - epidemiology | Bleomycin - administration & dosage | Bleomycin - adverse effects | Germany - epidemiology | Randomized Controlled Trials as Topic | Pregnancy | Testis - physiology | Hodgkin Disease - blood | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus
Journal Article
Fertility and Sterility, ISSN 0015-0282, 2014, Volume 102, Issue 3, pp. 667 - 674.e3
Objective To determine consequences of lymphoma treatments on sperm characteristics and sperm DNA, and to evaluate predictors of sperm recovery. Design... 
Internal Medicine | Obstetrics and Gynecology | sperm DNA | sperm chromatin | radiotherapy | spermatogenesis | Hodgkin | Lymphoma | chemotherapy | DNA INTEGRITY | FERTILITY PRESERVATION | CHROMATIN-STRUCTURE | TESTICULAR CANCER | CRYOPRESERVATION | SEMEN QUALITY | OBSTETRICS & GYNECOLOGY | REPRODUCTIVE BIOLOGY | HODGKINS-DISEASE | MEN | GONADAL DYSFUNCTION | Doxorubicin - therapeutic use | Sperm Count | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Mechlorethamine - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | DNA - radiation effects | Mechlorethamine - therapeutic use | Case-Control Studies | Cyclophosphamide - therapeutic use | Young Adult | Bleomycin - therapeutic use | Vinblastine - adverse effects | Adult | DNA - drug effects | Spermatogenesis - radiation effects | Spermatogenesis - drug effects | Prednisone - adverse effects | Spermatozoa - radiation effects | Semen Analysis | Combined Modality Therapy | Bleomycin - adverse effects | Spermatozoa - drug effects | DNA - chemistry | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Hodgkin Disease - therapy | Vincristine - therapeutic use | Vincristine - adverse effects | Spermatozoa - physiology | DNA Damage | Longitudinal Studies | Doxorubicin - adverse effects | Prednisone - therapeutic use | Care and treatment | Spermatozoa | Lymphomas | Drug therapy | DNA | Cancer
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 6, pp. 684 - 691
Journal Article